{
    "id": 485,
    "fullName": "FGFR1 wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type FGFR1 indicates that no mutation has been detected within the FGFR1 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2260,
        "geneSymbol": "FGFR1",
        "terms": [
            "FGFR1",
            "bFGF-R-1",
            "BFGFR",
            "CD331",
            "CEK",
            "ECCL",
            "FGFBR",
            "FGFR-1",
            "FLG",
            "FLT-2",
            "FLT2",
            "HBGFR",
            "HH2",
            "HRTFDS",
            "KAL2",
            "N-SAM",
            "OGD"
        ]
    },
    "variant": "wild-type",
    "createDate": "05/05/2014",
    "updateDate": "04/18/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3537,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ER-positive breast cancer cells with wild-type FGFR1 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).",
            "molecularProfile": {
                "id": 542,
                "profileName": "FGFR1 wild-type"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 311,
                    "pubMedId": 22238366,
                    "title": "Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22238366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6867,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGFR1 non-amplified lung cancer cell lines demonstrated reduced sensitivity to AZD4547 induced growth inhibition in culture and in xenograft models (PMID: 23082000).",
            "molecularProfile": {
                "id": 542,
                "profileName": "FGFR1 wild-type"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5821,
                    "pubMedId": 23082000,
                    "title": "Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23082000"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3542,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring mutant EGFR and wild-type FGFR1 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).",
            "molecularProfile": {
                "id": 13351,
                "profileName": "EGFR mut FGFR1 wild-type"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 311,
                    "pubMedId": 22238366,
                    "title": "Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22238366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 542,
            "profileName": "FGFR1 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 13348,
            "profileName": "ESR1 pos FGFR1 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 13351,
            "profileName": "EGFR mut FGFR1 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}